Universe Pharmaceuticals INC balance sheet UPC
As of Sep 30, 2025, Universe Pharmaceuticals INC had total assets of $69.3 billion and total liabilities of $13.2 billion. Total assets were up 2.0% from a year earlier. Stockholders' equity was $56.1 billion. It held $33.6 billion in cash and investments against $9.3 billion of total debt, net cash of $24.3 billion. The current ratio, current assets divided by current liabilities, was 4.07.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.
| Line |
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
|---|---|---|---|---|---|
| Assets | |||||
| Cash |
33,592
+13.9%
|
29,498
+558013.8%
|
5
-7.5%
|
6
-29.3%
|
8
|
| Short-term investments |
—
|
—
|
13
+0.5%
|
13
-4.2%
|
14
|
| Cash and investments |
33,592
+13.9%
|
29,498
+159310.4%
|
19
-1.9%
|
19
-13.5%
|
22
|
| Receivables |
13,008
+0.8%
|
12,906
+117066.9%
|
11
-27.5%
|
15
-2.5%
|
16
|
| Inventory |
2,193
+26.3%
|
1,737
+51856.8%
|
3
+51.5%
|
2
-10.4%
|
2
|
| Total current assets |
53,604
+3.8%
|
51,638
+204246.6%
|
25
-39.1%
|
42
-17.8%
|
50
|
| Property and equipment, net |
3,584
+0.4%
|
3,568
+96334.7%
|
4
-13.0%
|
4
-9.2%
|
5
|
| Total assets |
69,303
+2.0%
|
67,953
+162762.2%
|
42
-29.9%
|
60
-15.1%
|
70
|
| Liabilities and equity | |||||
| Accounts payable |
1,670
-66.0%
|
4,915
+107085.6%
|
5
+49.1%
|
3
-42.1%
|
5
|
| Total current liabilities |
13,174
-35.1%
|
20,313
+147584.2%
|
14
+5.0%
|
13
+16.8%
|
11
|
| Total liabilities |
13,174
-41.3%
|
22,450
|
—
|
—
|
—
|
| Stockholders' equity |
56,130
+23.4%
|
45,503
+62.7%
|
27,970
-20.8%
|
35,331
+75083.6%
|
47
|
| Debt | |||||
| Debt due within a year |
9,257
+58.1%
|
5,857
+427205.1%
|
—
|
4
-9.2%
|
4
|
| Total debt |
9,257
+58.1%
|
5,857
+427205.1%
|
—
|
4
-9.2%
|
4
|
| Net cash |
24,335
+2.9%
|
23,641
+137880.0%
|
—
|
15
-14.6%
|
17
|
| Ratios | |||||
| Current ratio |
4.07x
|
2.54x
|
1.84x
|
3.17x
|
4.50x
|
| Debt to equity |
0.16x
|
0.13x
|
—
|
0.00x
|
0.09x
|
| Return on equity |
-6.54%
|
-19.18%
|
-23.53%
|
-0.02%
|
—
|
| Return on assets |
-5.30%
|
-12.84%
|
-15,772.57%
|
-13.28%
|
—
|
| Book value per share |
99,637.36
|
1,061,169.33
|
4,614,014.02
|
9,746.35
|
2.16
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UPC (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- China
- Headquarters
- Ji'An, Jiangxi, China
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1809616
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.